UNSPSC 51413905: Flosatidil

This classification denotes a vasodilating agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 19S89CMO38. European Medicines Agency schedules Flosatidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07653MIG. Flosatidil generally arises in the molecular formula C26H34F3N3O3S.

UNSPSC 51413905 Flosatidil, a Commodity code, represents pharmaceutical supply procurement by state and local governments for emergency medical services and health benefit programs. State and local buyers are sourcing individual medication line items and broader generic pharmaceutical product portfolios to support fire rescue operations, state health agencies, and multistate cooperative purchasing groups. The issuing bodies span municipal fire departments, state health and human services commissions, and statewide cooperative purchasing alliances administering contracts on behalf of participating jurisdictions.

Recent activity shows geographic spread across Texas, Florida, Minnesota, and Oregon. The City of Tampa's Purchasing Department issued an IFB (Solicitation 26P00188) in April 2026 for Advanced Life Support Medications—Labetalol, Epinephrine, Adenosine, and Diltiazem—for Tampa Fire Rescue, with an estimated contract value of $40,000 and a Small Local Business Enterprise set-aside designation offering a 5 percent bid discount. The Texas Health and Human Services Commission posted an RFI (HHS0017013) in April 2026 to explore direct-to-manufacturer prescription fulfillment models for state pharmacy benefit programs. The Minnesota Department of Administration, administering the Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP (S1070000015802) with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities in Minnesota and Oregon, requiring products through authorized wholesalers including AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with contract effectiveness set for July 1, 2026, and pricing weighted at 75 percent of evaluation criteria.